S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)

EyePoint Pharmaceuticals (EYPT) Stock Price, News & Analysis

$23.11
-0.45 (-1.91%)
(As of 12/29/2023 ET)
Today's Range
$22.12
$23.82
50-Day Range
$5.71
$24.13
52-Week Range
$2.21
$24.62
Volume
926,194 shs
Average Volume
3.08 million shs
Market Capitalization
$1.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.50

EyePoint Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
40.6% Upside
$32.50 Price Target
Short Interest
Healthy
10.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.61mentions of EyePoint Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$51.87 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.05) to ($1.95) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

70th out of 950 stocks

Analytical Instruments Industry

4th out of 26 stocks


EYPT stock logo

About EyePoint Pharmaceuticals Stock (NASDAQ:EYPT)

EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The company's pipeline leverages its proprietary erodible Durasert E technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment, which is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EYPT Stock Price History

EYPT Stock News Headlines

MarketBeat All Access New Year's Sale - Just $1.00
Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.
MarketBeat All Access New Year's Sale - Just $1.00
Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.
Insider Sell Alert: Chief Corp Dev. & Strat.
Insider Sell Alert: Chief Corp Dev. & Strat. ...
See More Headlines
Receive EYPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/31/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/07/2024

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EYPT
Employees
144
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$32.50
High Stock Price Target
$44.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+40.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-102,250,000.00
Net Margins
-235.51%
Pretax Margin
-235.51%

Debt

Sales & Book Value

Annual Sales
$41.40 million
Book Value
$2.83 per share

Miscellaneous

Free Float
40,931,000
Market Cap
$1.09 billion
Optionable
Optionable
Beta
1.25

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Jay S. Duker M.D. (Age 64)
    President, CEO & Director
    Comp: $848.5k
  • Mr. Michael Pine (Age 47)
    Chief Business Officer
    Comp: $764.85k
  • Mr. George O. Elston (Age 58)
    Executive VP & CFO
    Comp: $743.86k
  • Mr. Michael J. Maciocio
    Senior Vice President of Manufacturing & Operations
  • Mr. Said Saim Ph.D. (Age 65)
    Senior VP & CTO
  • Mr. Ron I. Honig Esq.
    Chief Legal Officer & Company Secretary
  • Ms. Jennifer Leonard
    Chief People Officer & Senior VP of IT
  • Dr. Dario A. Paggiarino (Age 66)
    Senior VP & Chief Medical Officer
    Comp: $694.19k
  • Mr. David Scott Jones (Age 56)
    Senior VP & Chief Commercial Officer
    Comp: $672.08k
  • Ms. Isabelle Lefebvre
    Chief Regulatory Officer














EYPT Stock Analysis - Frequently Asked Questions

Should I buy or sell EyePoint Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EYPT shares.
View EYPT analyst ratings
or view top-rated stocks.

What is EyePoint Pharmaceuticals' stock price target for 2024?

6 equities research analysts have issued 1 year price targets for EyePoint Pharmaceuticals' stock. Their EYPT share price targets range from $22.00 to $44.00. On average, they anticipate the company's stock price to reach $32.50 in the next twelve months. This suggests a possible upside of 40.6% from the stock's current price.
View analysts price targets for EYPT
or view top-rated stocks among Wall Street analysts.

How have EYPT shares performed in 2023?

EyePoint Pharmaceuticals' stock was trading at $3.50 at the start of the year. Since then, EYPT stock has increased by 560.3% and is now trading at $23.11.
View the best growth stocks for 2023 here
.

When is EyePoint Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our EYPT earnings forecast
.

How were EyePoint Pharmaceuticals' earnings last quarter?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) announced its quarterly earnings data on Wednesday, November, 1st. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.29. The company had revenue of $15.20 million for the quarter, compared to analyst estimates of $3.90 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 109.34% and a negative net margin of 235.51%.

When did EyePoint Pharmaceuticals' stock split?

EyePoint Pharmaceuticals shares reverse split on the morning of Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of EyePoint Pharmaceuticals own?
How do I buy shares of EyePoint Pharmaceuticals?

Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EYPT) was last updated on 12/31/2023 by MarketBeat.com Staff

My Account -